Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Catalyst Pharmaceuticals (NASDAQ: CPRX), a commercial-stage biopharmaceutical company specializing in rare and difficult-to-treat diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President and CEO, Richard J. Daly, will deliver a presentation on Thursday, January 16, 2025, at 10:30 am PST in San Francisco.
The presentation will be accessible via webcast through the Investors section of Catalyst's website, with a replay available for a minimum of 30 days following the event. This conference represents a significant platform for Catalyst to showcase its developments in novel medicines and treatments.
Catalyst Pharmaceuticals (NASDAQ: CPRX), un'azienda biofarmaceutica in fase commerciale che si specializza in malattie rare e difficili da trattare, ha annunciato la propria partecipazione al 43° Annual J.P. Morgan Healthcare Conference. Il Presidente e CEO dell'azienda, Richard J. Daly, presenterà una relazione giovedì 16 gennaio 2025, alle 10:30 PST a San Francisco.
La presentazione sarà accessibile tramite webcast nella sezione Investitori del sito di Catalyst, con una registrazione disponibile per un minimo di 30 giorni dopo l'evento. Questa conferenza rappresenta una piattaforma significativa per Catalyst per mostrare i propri sviluppi in nuove medicine e trattamenti.
Catalyst Pharmaceuticals (NASDAQ: CPRX), una empresa biofarmacéutica en etapa comercial especializada en enfermedades raras y difíciles de tratar, ha anunciado su participación en la 43ª Conferencia Anual de J.P. Morgan Healthcare. El presidente y CEO de la compañía, Richard J. Daly, realizará una presentación el jueves 16 de enero de 2025, a las 10:30 am PST en San Francisco.
La presentación será accesible a través de un webcast en la sección de Inversores del sitio web de Catalyst, con una repetición disponible por un mínimo de 30 días después del evento. Esta conferencia representa una plataforma significativa para que Catalyst exhiba sus desarrollos en nuevas medicinas y tratamientos.
카탈리스트 제약(Catalyst Pharmaceuticals) (NASDAQ: CPRX)는 희귀하고 치료가 어려운 질병을 전문으로 하는 상업 단계의 생명공학 회사로, 제43회 JP 모건 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 회사의 회장 겸 CEO인 리처드 J. 달리(Richard J. Daly)는 2025년 1월 16일 목요일 오전 10시 30분 PST에 샌프란시스코에서 발표를 진행할 예정입니다.
발표는 카탈리스트의 웹사이트 투자자 섹션을 통해 웹캐스트로 접근할 수 있으며, 행사 이후 최소 30일간 다시 볼 수 있는 재생이 제공됩니다. 이번 컨퍼런스는 카탈리스트가 새로운 의약품 및 치료법의 발전을 선보일 수 있는 중요한 플랫폼입니다.
Catalyst Pharmaceuticals (NASDAQ: CPRX), une entreprise biopharmaceutique en phase commerciale spécialisée dans les maladies rares et difficiles à traiter, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare. Le président et directeur général de l'entreprise, Richard J. Daly, fera une présentation le jeudi 16 janvier 2025 à 10h30 PST à San Francisco.
La présentation sera accessible par webcast dans la section Investisseurs du site de Catalyst, avec un replay disponible pendant un minimum de 30 jours après l'événement. Cette conférence représente une plateforme significative pour Catalyst afin de mettre en avant ses développements en matière de nouveaux médicaments et traitements.
Catalyst Pharmaceuticals (NASDAQ: CPRX), ein biopharmazeutisches Unternehmen in der Handelsphase, das sich auf seltene und schwer behandelbare Krankheiten spezialisiert hat, hat seine Teilnahme an der 43. J.P. Morgan Healthcare Conference angekündigt. Der Präsident und CEO des Unternehmens, Richard J. Daly, wird am Donnerstag, den 16. Januar 2025, um 10:30 Uhr PST in San Francisco eine Präsentation halten.
Die Präsentation wird über einen Webcast im Investorenbereich der Website von Catalyst zugänglich sein, und eine Aufzeichnung wird für mindestens 30 Tage nach der Veranstaltung verfügbar sein. Diese Konferenz stellt eine bedeutende Plattform für Catalyst dar, um seine Entwicklungen in neuartigen Medikamenten und Behandlungen vorzustellen.
- None.
- None.
CORAL GABLES, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025 in San Francisco, CA.
43rd Annual J.P. Morgan Healthcare Conference Presentation Details
| Date: | Thursday, January 16, 2025 | |
| Time: | 10:30 am PST | |
| Webcast: | Link | |
The webcast will be available under the Investors section on the Company's website at www.catalystpharma.com, and a replay will be available for at least 30 days.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst, headquartered in Coral Gables, FL., was recognized as one of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List.
For more information, please visit Catalyst's website at www.catalystpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2023 and its other filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
FAQ
When is Catalyst Pharmaceuticals (CPRX) presenting at the J.P. Morgan Healthcare Conference 2025?
How can investors watch Catalyst Pharmaceuticals' J.P. Morgan Healthcare Conference presentation?
What is the focus area of Catalyst Pharmaceuticals (CPRX)?
How long will the replay of CPRX's J.P. Morgan Healthcare Conference presentation be available?
